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Abstract
Background: Remifentanil is an effective drug for protecting against adverse haemodynamic responses to tracheal
intubation. We compared the haemodynamic responses during anaesthesia induction between continuous
intravenous (IV) infusion and two bolus injections of remifentanil.
Methods: This prospective, randomised, open-label, single-centre study included patients with American Society of
Anesthesiologists physical status I-II, scheduled to undergo elective surgery under general anaesthesia. Patients
were randomised into two groups based on remifentanil administration type: the continuous IV infusion group
(Group C) receiving a 0.3-μg/kg/min remifentanil infusion for 5 min followed by a 0.1-μg/kg/min remifentanil
infusion, and the IV bolus group (Group B) receiving a combination of two bolus injections of remifentanil (first
bolus of 0.4 μg/kg and second bolus of 0.6 μg/kg after 3 min) and 0.1 μg/kg/min remifentanil. General anaesthesia
was induced with 1 mg/kg propofol and 0.6 mg/kg rocuronium 3 min after remifentanil infusion (Group C) or
immediately after the first bolus of remifentanil (Group B). Tracheal intubation was performed 4 min after the
injection of propofol and rocuronium. Heart rate and non-invasive blood pressure were recorded at 1-min intervals
from baseline (i.e., before induction) to 5 min after tracheal intubation.
Results: A total of 107 patients were enrolled (Group C, 55; Group B, 52). Normotensive patients with no history of
antihypertensive medication use were assigned to the normotensive subgroup (41 each in both groups), while
those with hypertension but without a history of antihypertensive medication use were assigned to the untreated
hypertensive subgroup (Group C vs. B, n = 7 vs. 4). Finally, patients with a history of antihypertensive medication use
were assigned to the treated hypertensive subgroup (7 each in both Groups C and B). No differences in heart rate
and blood pressure were observed between Groups C and B within each subgroup.
Conclusions: Haemodynamic responses during anaesthesia induction were similar between continuous infusion and
two bolus injections of remifentanil within both normotensive and hypertensive patients with or without medication.
Trial registration: The trial was retrospectively registered with Japanese Clinical Trial Registry “UMIN-CTR” on 20
October 2016 and was given a trial ID number UMIN000024495.
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Background
Remifentanil is a rapid-onset and ultra-short acting opi-
oid [1–3]. Since laryngoscopy and tracheal intubation
can result in tachycardia and hypertension, remifentanil
is commonly used not only to maintain anaesthesia, but
also to attenuate adverse haemodynamic changes due to
tracheal intubation [4–6]. To raise the effect-site
concentration of remifentanil quickly, it is infused at
higher concentrations or injected in bolus doses prior to
constant continuous infusion. However, differences in
haemodynamics during anaesthesia induction between
continuous infusion and bolus injection of remifentanil
have not yet been investigated. In addition, it remains
unclear which method is best suited to hypertensive
patients in whom tachycardia and hypertension by in-
tubation may be exaggerated.
The aims of this randomised open-label study were to
compare the haemodynamic responses during anaesthe-
sia induction between continuous intravenous infusion
and bolus injections of remifentanil in normotensive pa-
tients, as well as in treated and untreated hypertensive
patients.
Methods
Ethics and study design
This study was approved by the hospital ethics commit-
tee for human studies (Ethical Committee number
2013–079; Chairperson Professor Koichiro Itai) on 3 Oc-
tober 2013, and all patients provided informed written
consent. American Society of Anesthesiologists physical
status (ASA) I-II patients scheduled for elective surgery
under general anaesthesia were prospectively enrolled.
Exclusion criteria included patients younger than 20 years
of age and with the presence of cardiovascular or
cerebrovascular disease, renal failure, or a predicted diffi-
cult airway. If tracheal intubation was not performed
within 1 min, this patient was excluded.
Normotensive patients with no history of antihyperten-
sive medication use were assigned to the normotensive
patients subgroup, while those with hypertension (systolic
blood pressure (SBP) > 140 mmHg) were assigned to the
untreated hypertensive (HT) patient subgroup. Hyperten-
sive patients with a history of antihypertensive medication
use were assigned to the treated HT patients subgroup.
Using a stratified permuted block randomization method,
normotensive patients were randomized to two groups of
remifentanil administration type; the continuous intraven-
ous (IV) infusion group (Group C) and the IV bolus group
(Group B). Group C patients received a 0.3 μg/kg/min
infusion of remifentanil for five minutes followed by a
0.1 μg/kg/min infusion of remifentanil, and Group B pa-
tients received a combination of two bolus injections of
remifentanil (first bolus of 0.4 μg/kg and second bolus of
0.6 μg/kg in a 3 min interval) with 0.1 μg/kg/min remifen-
tanil. The treated HT and untreated HT patients were also
randomized into two groups using a simple randomization
method by random number tables. The time courses of
anaesthesia induction in Group C and B are shown in
Fig. 1. General anaesthesia was induced using 1 mg/kg
propofol and 0.6 mg/kg rocuronium 3 min after infusion
of remifentanil in Group C or immediately after the first
bolus of remifentanil in Group B. An additional 10 mg of
propofol was administrated every 10 s until there was
a loss of verbal response. Tracheal intubation was
performed 4 min after induction of anaesthesia
(7 min after the infusion of remifentanil in Group C
or 4 min after the first bolus of remifentanil in Group
B), at which estimated effect-site concentration of
a) Group C
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Fig. 1 The time course of plasma and effect-site concentration of remifentanil in Group C (a) and Group B (b). The plasma and effect-site concentrations
of remifentanil were calculated using the Egan model, which was a default formula used in PrimeGaia, the electronic anaesthesia record
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remifentanil was approximately 4 ng/ml in each
group. After intubation, general anaesthesia was main-
tained with 1.5–2 % inspired sevoflurane and 0.1 μg/
kg/min remifentanil in both groups.
Measurements
Heart rate (HR) and non-invasive blood pressure (NIBP)
were recorded at 1-min intervals from baseline (prior to
induction) to 5 min after tracheal intubation. NIBP every
1 min is not always possible due to time taken for each
measurement and has the potential to affect subsequent
mesurements. However, it was considered that invasive
blood pressure measurement was not suitable for this
study, because almost patients were performed minor
surgeries. If NIBP measurement was failed, this patient
was excluded. If HR or SBP decreased to less than
50 bpm or 70 mmHg respectively, IV of 4 mg ephedrine
was deemed necessary. The estimated effect-site concen-
tration of remifentanil was calculated with the Egan
model [7] in the electronic Anaesthesia record “Prime-
Gaia” (Nihon Kohden, Tokyo, Japan).
Statistical analysis
A prior sample size calculation was performed, which
revealed that 30 patients per group would have an
80 % power with a p < 0.05 to detect 15 mmHg differ-
ences in mean arterial pressure between groups (α =
0.05, β = 0.2). All data are presented as mean ± stand-
ard deviation (SD), numbers or percentage. Statistical
analysis was performed using the program JMP 11
(SAS Institute Inc, Cary, NC, USA). Categorical data
were examined using a chi-square test or Fisher’s
exact test to compare groups. One-way ANOVA for
repeated measures was used to analyse changes over
time. Significance (p < 0.05) was determined by one-
way ANOVA with post hoc mean comparison by the
Tukey-Kramer honestly significant difference (HSD)
test. The student’s t test was used when means of
two groups were compared.
Results
A total of 107 patients were recruited from October
2013 to June 2015. Patient characteristics are shown
in Table 1. There were 82 normotensive patients
older than 20 years of age (n = 41 in both groups),
14 treated HT patients (n = 7 in both groups) and 11
untreated HT patients (n = 7 in Group C and n = 4
in Group B). Both the treated and untreated HT
subgroups were compared between Group C and
Group B. In both normotensive and treated HT pa-
tients, there were no significant differences between
Group C and Group B in age, gender, height, weight,
BMI, and ASA (Table 1). Anti-hypertensive medica-
tions which treated hypertension patients were tak-
ing are shown in Table 2. Ca blocker was continued
through the morning of surgery, and angiotensin II
receptor blocker was continued through the day be-
fore surgery. There were no significant differences
between Group C and Group B in anti-hypertensive
medications.
Comparison of haemodynamic changes during
anaesthesia induction between Group C and Group B
Comparisons of HR, SBP, diastolic blood pressure
(DBP), and mean blood pressure (MBP) in normoten-
sive patients between Group C and Group B are
shown in Table 3 and illustrated in Fig. 2. There were
Table 1 Data characteristics of patients, stratified by group













Age (year) 46 ± 16 66 ± 9 57 ± 13 45 ± 16 67 ± 5 63 ± 7
Male/Female 21/20 4/3 2/5 21/20 7/0 2/2
Height (cm) 161 ± 8 158 ± 8 155 ± 6 162 ± 8 162 ± 13 160 ± 15
Weight (kg) 57 ± 10 59 ± 9 55 ± 5 60 ± 9 66 ± 13 57 ± 11
BMI 21.8 ± 3.1 23.7 ± 3.5 22.7 ± 2.8 22.7 ± 2.8 24.8 ± 2.9 22.3 ± 1.0
ASA I/II 28/13 0/7 0/7 27/14 0/7 0/4
The results are expressed as mean ± SD or numbers of patients. Normotensive: patients with no history of antihypertensive medication use and with
normotension, treated HT: patients with history of antihypertensive medication use, untreated HT: patients with no history of antihypertensive medication use and
with hypertension, HT hypertensive, BMI body mass index, ASA American Society of Anesthesiologists physical status
Table 2 Antihypertensive medication in treated hypertensive
patients
Group C Group B
Subgroups Treated HT (n = 7) Treated HT (n = 7)
Ca blocker 5 (72 %) 3 (42 %)
ARB 1 (14 %) 2 (29 %)
Ca blocker + ARB 1 (14 %) 2 (29 %)
The results are expressed as numbers and %. Ca blocker was continued
through the morning of surgery, and ARB was continued through the day
before surgery. Treated HT: patients with a history of antihypertensive
medication use, HT hypertensive, ARB angiotensin II receptor blocker
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no significant differences between the groups for any
parameters at any time points. When compared to
baseline, HR was not significantly different at any
time points in either group; however, upon compari-
son between immediately before tracheal intubation
(Tind) and immediately after tracheal intubation (T0),
SBP, DBP, and MBP were significantly decreased com-
pared to baseline in each group.
Comparisons of HR, SBP, DBP, and MBP within
treated and untreated HT patients between Group C
and Group B are shown in Table 3 and illustrated in
Figs. 3 and 4, respectively. There were no significant
Table 3 Haemodynamic data during anaesthesia induction













HR (bpm) Baseline 70 ± 8 74 ± 13 68 ± 19 77 ± 12 74 ± 23 70 ± 10
Tind 62 ± 10 67 ± 10 59 ± 9 64 ± 11 61 ± 17 62 ± 10
T0 77 ± 20 80 ± 16 72 ± 15 68 ± 13 66 ± 11 87 ± 18
T1 76 ± 13 77 ± 12 72 ± 15 82 ± 16 74 ± 20 80 ± 15
T2 72 ± 10 74 ± 13 68 ± 14 78 ± 18 69 ± 19 73 ± 14
T3 70 ± 9 71 ± 11 69 ± 13 72 ± 17 66 ± 16 70 ± 12
T4 68 ± 10 70 ± 11 67 ± 11 70 ± 13 66 ± 17 66 ± 9
T5 67 ± 10 70 ± 10 66 ± 11 71 ± 19 61 ± 13 68 ± 9
SBP (mmHg) Baseline 123 ± 14 122 ± 13 145 ± 19 136 ± 19 153 ± 9 154 ± 11
Tind 81 ± 18* 80 ± 12* 79 ± 16* 80 ± 21* 93 ± 14* 100 ± 16*
T0 92 ± 30* 100 ± 17* 97 ± 20* 98 ± 26* 109 ± 36* 153 ± 40
T1 96 ± 25* 107 ± 18* 107 ± 23* 124 ± 41 133 ± 42 147 ± 15
T2 94 ± 25* 101 ± 15* 103 ± 22* 122 ± 46 123 ± 42 151 ± 46
T3 88 ± 18* 96 ± 20* 104 ± 21* 115 ± 30 112 ± 40* 123 ± 17
T4 86 ± 16* 93 ± 20* 96 ± 15* 109 ± 26* 111 ± 37* 116 ± 21*
T5 87 ± 17* 90 ± 17* 95 ± 15* 102 ± 19* 106 ± 31* 115 ± 10*
DBP (mmHg) Baseline 76 ± 14 77 ± 14 82 ± 19 82 ± 7 86 ± 9 92 ± 11
Tind 47 ± 14* 49 ± 10* 48 ± 15* 51 ± 9* 50 ± 7* 66 ± 17*
T0 61 ± 23 66 ± 17 62 ± 17 65 ± 13* 70 ± 32 99 ± 25
T1 62 ± 23 69 ± 16 68 ± 16 75 ± 22 75 ± 31 96 ± 21
T2 58 ± 19 66 ± 17* 62 ± 14* 74 ± 20 70 ± 27 86 ± 26
T3 55 ± 16* 62 ± 16* 61 ± 12* 68 ± 15* 63 ± 24* 77 ± 17
T4 53 ± 14* 59 ± 17* 58 ± 10* 68 ± 15* 60 ± 21* 73 ± 16
T5 52 ± 12* 57 ± 15* 57 ± 10* 62 ± 7* 57 ± 19* 72 ± 11*
MBP (mmHg) Baseline 90 ± 11 89 ± 10 101 ± 29 97 ± 6 105 ± 12 114 ± 14
Tind 58 ± 12* 59 ± 10* 57 ± 15* 59 ± 14* 66 ± 11* 73 ± 19*
T0 73 ± 22 78 ± 19 73 ± 17* 73 ± 16* 82 ± 31 115 ± 32
T1 72 ± 18 79 ± 16 80 ± 17 92 ± 27 92 ± 36 111 ± 14
T2 68 ± 16* 77 ± 18* 75 ± 17 91 ± 36 88 ± 30 100 ± 31
T3 65 ± 14* 73 ± 16* 72 ± 15* 83 ± 21 81 ± 24* 89 ± 20
T4 64 ± 12* 71 ± 20* 69 ± 11* 78 ± 15* 80 ± 26* 88 ± 15*
T5 62 ± 11* 69 ± 16* 68 ± 10* 74 ± 12* 76 ± 20* 87 ± 13*
The results are expressed as mean ± SD. Haemodynamic variables were recorded before induction of general anaesthesia (baseline), immediately before tracheal
intubation (Tind), immediately after tracheal intubation (T0), and every minute for 5 min following tracheal intubation (T1-T5)
*p < 0.05, compared with baseline within each group
HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, MBP mean blood pressure
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differences between groups for any parameters at any
time points in each subgroup.
Use of additional propofol and adverse events
Use of additional propofol and adverse events includ-
ing HR < 50 bpm, SBP < 70 mmHg, and use of ephe-
drine are shown in Table 4 and illustrated in Fig. 5.
There were no significant differences between groups
in each subgroup. In normotensive patients, 55 % of
patients in Group C required additional propofol,
compared to 59 % of patients in Group B. Addition-
ally, when age was categorized, patients younger than
60 years required more propofol (Group C vs. Group
B: 20–29 years old: 86 % vs. 63 %, 30–39: 75 % vs.
63 %, 40–49: 56 % vs. 100 %, 50–59: 45 % vs. 55 %,
over 60: 0 % vs. 14 %). In the untreated HT sub-
group, SBP was never under 70 mmHg and ephedrine
was never used.
Discussion
In this study, we demonstrated that a 0.3-μg/kg/min
infusion of remifentanil for 5 min followed by a 0.1-
μg/kg/min infusion did not differ significantly from a
combination of two bolus injections of remifentanil
(first bolus of 0.4 μg/kg and second bolus of 0.6 μg/
kg after 3 min) and 0.1-μg/kg/min infusion of remi-
fentanil in terms of haemodynamic responses during
the induction of anaesthesia, in both normotensive
patients and patients with hypertension, with or
without treatment. In both remifentanil groups, HR
deceased following anaesthesia induction and in-
creased after intubation when compared to baseline
HR; however, this was not significant. Blood pressure
was significantly decreased from baseline after anaes-
thesia induction and once increased upon intubation,
but again decreased from baseline after intubation.
However, these changes in blood pressure were not
considered clinically significant. In the treated and
untreated HT patients, Group C maintained baseline
blood pressure after intubation for longer than
Group B.
The cardiovascular response to anaesthesia induc-
tion, laryngoscopy, and tracheal intubation may be ex-
aggerated in the treated or untreated HT patients [8].
Maguire et al. reported that a bolus dose of remifen-
tanil 0.5 μg/kg followed by a 0.1 μg/kg/min infusion
*
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Fig. 2 Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean blood pressure (MBP), stratified by group, for
normotensive patients (mean ± SD). Haemodynamic variables were recorded before induction of general anaesthesia (baseline), immediately before
tracheal intubation (Tind), immediately after tracheal intubation (T0), and every minute for 5 min following tracheal intubation (T1-T2). *p < 0.05,
compared with baseline within each group
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could well control the haemodynamic response to in-
tubation in treated HT patients. However, the in-
crease in blood pressure was approximately 30 mmHg
during this regimen, compared to a 10 mmHg in-
crease in young adults who received a bolus dose of
remifentanil 0.5 μg/kg followed by a 0.25 μg/kg/min
infusion [8]. Park et al. demonstrated that a low-dose
regimen of remifentanil, consisting of a 0.5 μg/kg
bolus followed by a continuous infusion of 0.1 μg/kg/
min, resulted in similar haemodynamic responses to
induction and tracheal intubation in normotensive
and treated or untreated HT patients, however un-
treated HT patients were shown to have a relatively
large amplitude of pressure swing [9]. Our study also
demonstrated that hypertensive patients had larger
swings in haemodynamic response to anaesthesia in-
duction and tracheal intubation than normotensive
patients; conversely, untreated HT patients had no
adverse hypotension (SBP < 70 mmHg) in either
group, whereas 2 of treated HT patients (29 %) had
adverse hypotension in each group. Treated HT pa-
tients might be easy to have SBP < 70 mmHg, because
SBP at baseline in treated HT was lower than that in
untreated HT and the haemodynamic depression in
response to anaesthesia induction were not different
between treated HT and untreated HT, as shown in
Table 3. On the basis of these findings, the low-dose
regimen of remifentanil was also shown to be effect-
ive at stabilizing haemodynamics prior to intubation,
and limiting pressure responses to tracheal intubation
without excessive cardiovascular depression. Besides,
the remifentanil administration methods to 2 groups
in this study were also low-dose regimens like those
of Maguire and Park’s reports.
Remifentanil is a rapid-onset and ultra-short acting
pain relief opioid. Although multiple drugs such as lido-
caine [10], opioids [8, 11, 12], β-blockers [13, 14], dex-
medetomidine [15] and volatile anaesthetics [16] can be
used to attenuate tachycardia and hypertension due to
tracheal intubation, remifentanil is considered to have
the ideal pharmacological character to treat adverse
haemodynamic response due to a noxious but brief
stimulation of tracheal intubation. However, much
higher rates of infusion or bolus doses of remifentanil
than those used in our study were associated to brady-
cardia and/or hypotension [4, 5]. The separated bolus
method of Group B may be effective in avoiding exces-
sive cardiovascular depression before intubation.
*
* * * * * *
* * * *
*












Fig. 3 Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean blood pressure (MBP), stratified by group, for treated
hypertensive patients (mean ± SD). Haemodynamic variables were recorded before induction of general anaesthesia (baseline), immediately before tracheal
intubation (Tind), immediately after tracheal intubation (T0), and every minute for 5 min following tracheal intubation (T1-T2). *p< 0.05, compared with
baseline within each group
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General anaesthesia was induced with 1 mg/kg pro-
pofol and 0.6 mg/kg rocuronium, and an additional
10 mg of propofol was administrated every 10 s until
there was a loss of verbal response. Although stand-
ard propofol dose at induction is 1.5–2.5 mg/kg, opi-
oids reduce requirement dose of propofol for loss of
consciousness. In combination with remifantanil, 1.0–
1.5 mg propofol is sufficient for loss of consciousness
[17, 18]. The need for additional propofol was similar
between groups. When age was categorized, patients
younger than 60 years required more propofol, sug-
gesting that 1 mg/kg of propofol may not to be
enough for anaesthesia induction in patients under
60 years old even with remifentanil administration.
However, due to the individual minimum necessary
amount of propofol used for the anaesthesia induc-
tion, the suppressive effect of propofol on haemo-
dynamics may be limited in this study.
Thompson et al. reported that 50 % of patients
who received 1 μg/kg of remifentanil followed by an
infusion of 0.5 μg/kg/min, exhibited bradycardia (HR
< 45 bpm) and hypotension (SBP < 80 mmHg), and
required rescue medication [4]. In this study, adverse
events such as bradycardia (HR < 50 bpm) and








Fig. 4 Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean blood pressure (MBP), stratified by group, for
untreated hypertensive patients (mean ± SD). Haemodynamic variables were recorded before induction of general anaesthesia (baseline),
immediately before tracheal intubation (Tind), immediately after tracheal intubation (T0), and every minute for 5 min following tracheal intubation
(T1-T5). *p < 0.05, compared with baseline within each group
Table 4 Use of additional propofol and adverse events in patients, stratified by group













Additional Propofol 22 (55 %) 2 (29 %) 4 (57 %) 24 (59 %) 0 (0 %) 1 (25 %)
Adverse Events
HR < 50 bpm 3 (8 %) 1 (14 %) 2 (29 %) 3 (7 %) 2 (29 %) 0 (0 %)
SBP < 70 mmHg 8 (20 %) 2 (29 %) 0 (0 %) 9 (22 %) 2 (29 %) 0 (0 %)
Use of Ephedrine 8 (20 %) 2 (29 %) 0 (0 %) 4 (10 %) 2 (29 %) 0 (0 %)
The results are expressed as numbers and %. Normotensive: patients with no history of antihypertensive medication use and with normotension, treated HT:
patients with a history of antihypertensive medication use, untreated HT: patients with no history of antihypertensive medication use and with hypertension,
HT hypertensive
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hypotension (SBP < 70 mmHg) were similar between
groups. In both groups and subgroups, adverse
events occurred in less than 30 % of patients. This
lower incidence of adverse events could be related to
the lower infusion regimen and the separated bolus
injections.
Limitations
The Egan model was used to estimate plasma and
effect-cite concentration of remifentanil. In compari-
son to the Minto model [19], which is commonly
used to estimate remifentanil concentration, the Egan
model is not corrected for age. Hence, in the elderly,
the actual remifentanil concentration can be higher
than the estimated concentration. In addition, we
used actual weight to determine the dose of remifen-
tanil to be administered as it has been reported that
ideal body weight-based remifentanil infusion is po-
tentially insufficient for anaesthetic induction in obese
patients [20]. The sample sizes of treated and un-
treated HT subgroups were small and a larger ran-
domized study is needed to confirm these results.
Conclusions
Both the continuous and bolus regimen of remifenta-
nil reduced haemodynamic responses to intubation ef-
fectively, and resulted in similar haemodynamics
during induction of anaesthesia within normotensive
and hypertensive patients with or without anti-
hypertensive medication. In other words, separated
remifentanil boluses method was performed as safely
as continuous infusion method and would be able to
reduce time spent on anesthesia induction compared
to continuous infusion.
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